The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on hospitalized COVID-19 patients. Researchers concluded the antibody treatment was "unlikely to help."
Copyright 2020 NPR
Eli Lilly Ends Antibody Trial In Hospitalized COVID-19 Patients, Other Trials Go On
Corrected: October 26, 2020 at 10:00 PM MDT
An earlier version of this story incorrectly said President Trump had received bamlanivimab in combination with remdesivir while being treated for COVID-19. The president received only remdesivir, among other medications.
